

## **QUARTERLY REPORT Q1 2024**

January – March 2023

PEPTONIC medical AB (public) org nr 556776–3064

### **GROUP**

2024 FIRST QUARTER (January-March)

- Sales of products 10,808 (8,874) KSEK
- Gross profit 5,894 (4,869) KSEK, 55% (55%)
- Operating profit -10,548 (-6,654) KSEK
- Earnings per share - 0.01 (-0.01) SEK

---

### **IMPORTANT EVENTS DURING THE PERIOD**

- Extraordinary general meeting where Kristina Ingvar was elected to the company's board.
- Peptonic Medical expands its partnership with Farmasiet and launches the entire VagVitals product portfolio in Norway.
- Two new products were launched in February on the Swedish market: VagiVital Menopause self-care test and VagiVital self-care test for urinary tract infection.
- On February 6, the board appointed Anna Linton as the new CEO.
- Peptonic Medical announced in March that its subsidiary, Lune Group Oy, is filing for bankruptcy due to increased competition and negative operating results.

### **IMPORTANT EVENTS AFTER THE PERIOD**

- In April, an exclusive distribution agreement was signed for VagiVital and Vernivia for the Benelux region.
- Patents granted in the USA for treating and preventing fungal infections in women.
- On April 16, the board decided, subject to approval from the general meeting, on a rights issue of units of approximately SEK 61.4 million.
- On April 17, the Company called for the annual general meeting on May 21, 2024.

## LETTER FROM THE CEO

The first quarter has been marked by good growth, exhibiting positive development compared to both the same period of the previous year and the previous quarter. It's gratifying to see that our efforts are yielding results, and despite the loss of revenues from Lune, we managed to break the downward trend. Particularly in the Nordic region, we have witnessed significant growth, with sales increasing by 165% compared to the same quarter of the previous year. Vernivia has now begun to contribute positively to our results. In other markets, we have succeeded in maintaining sales at the same level as the previous year.

On the cost side, we continue to face an additional burden due to the merger with Pharmiva. Furthermore, we have strengthened our organization with key competencies to support continued growth and expansion.

The standout products in our portfolio from a sales perspective are VagiVital AktivGel, VagiVital Moisturizing Intimate Wash, and Vernivia. These three products constitute the cornerstones of the company's volume production, complemented by our self-care test for bacterial vaginosis. I have previously emphasized the importance of focusing our efforts on growth within our existing product portfolio. This strategic decision has led to a reduction in the number of new launches during the year. We see significant sales opportunities within these intimate self-care products and will now intensify our focus on them during the upcoming period.

In the American market, where we have strategically prioritized our sales focus, we continue to prepare for our own launch of company intimate self-care products. At the same time, our dialogue with the leading retail chains CVS and Walgreens continues to expand the range of our products sold under their own brands. We are also in ongoing discussions with Walmart. We are aware that the internal processes within these retail chains can be slow. Nevertheless, we see the opportunity for a quick positive impact on our sales if our products are approved, especially as they will be widely distributed in stores and sold under each chain's brand. By combining our own efforts with key partnerships, we are building a robust platform for growth and reaching a broader group of women in the market.

Our second significant focus for geographic expansion is Europe. However, I believe that our presence in the European market is not extensive enough. For this reason, we plan to intensify our efforts by strategically targeting three to four selected European markets. By focusing on these markets, we will secure distribution partnerships and accelerate our growth pace on the European stage.

The first quarter has been promising; despite the loss of revenues from Lune, we have managed to reverse a downward trend. We have a driven and competent organization and are focused on driving the growth of our key products. Our progress in the American market is promising, as well as our plans for expansion in Europe. Through strategic partnerships and focused efforts, we look forward to continuing our successful growth journey.

Anna Linton, VD

## **ABOUT THE COMPANY**

Peptonic Medical AB is a Swedish biomedical company engaged in the development and sale of clinically proven self-care products and self-diagnostic tests within women's intimate health. The portfolio is sold under the brands VagiVital and Vernivia.

The company aspires to a future where intimate health seamlessly integrates into women's self-care routines. Through a holistic approach, Peptonic empower women by offering solutions that enable them to autonomously diagnose, treat, and prevent intimate medical conditions. The vision is for women to feel empowered and confident in managing their intimate health, cultivating a profound sense of control and well-being.

Central to the growth strategy is the geographic expansion of VagiVital and Verniva through local partners, with Europe and the USA being prioritized markets. The company's business model is to operate the Nordic business in-house and primarily work with partners in other geographical markets. Peptonic Medical intends to continuously broaden the company's product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug-delivery technology, Venerol, and the gel base in VagiVital provide a solid foundation for expanding the portfolio.

### **Share**

Peptonic Medical has been listed on the Spotlight Stock Market since 2014 and trades under the ticker symbol: PMED. The share capital at the end of the reporting period amounted to SEK 38,371,139.9, divided into 1,534,845,596 outstanding shares with a par value of SEK 0.025 per share. The number of outstanding warrants amounted to 196,370,600.

### **Organization**

The group consists of the parent company Peptonic Medical AB (publ) headquartered in Stockholm, Sweden, along with its subsidiaries Common Sense Marketing Inc, USA, and Peptonic Medical Ltd in Israel. At the end of the period, the number of employees in the group was 28 (34), and for the parent company, it was 8 (3).

For further information, visit [www.peptonicmedical.se](http://www.peptonicmedical.se).

## FINANCIAL INFORMATION – GROUP

The merger with Pharmiva was integrated into the parent company during the fourth quarter of 2023. Pharmiva's accumulated results before the merger date and most of the merger-related costs were directly booked against the parent company's equity and do not affect the income statement. Starting from the merger date on November 21, Pharmiva is included in the group's operating results and balance sheet. During the first quarter of 2024, only Lune Group Oy is included in the results until March 12. It's important to note that the figures for the first quarter of 2024 are not directly comparable to the previous year due to changes in the group structure.

**Revenue** – Revenue for the first quarter amounted to 11,148 (9,067) KSEK, of which sales of goods accounted for 10,808 (8,874) KSEK. Sales of Vagivital, Vernivia, and partner-owned brands amounted to 9,105 (6,745) KSEK, an increase of 35% compared to the same period last year. Continued growth of 2,137 KSEK (165%) was seen in the Nordic region. The increase is partly due to Vernivia, which was added in connection with the merger from Pharmiva. Other regions maintained the same sales levels as the same period last year.

**Operating expenses** – During the first quarter, the group's expenses amounted to -21,546 (-15,721) KSEK. The change is mainly related to the merger with Pharmiva and restructuring in the organization. The cost of goods sold during the quarter was -4,914 (-4,005) KSEK, resulting in a gross margin of 55% (55%). Of these costs, depreciation amounted to -1,574 (-840) KSEK. Continuous work is being done to restructure and streamline the organization after the merger with Pharmiva.

**Result** – The group's result after financial items adjusted for comparison items amounted to -10,658 (-7,998) KSEK for the first quarter.

**Financial position and liquidity** – Cash and bank balances amounted to 3,192 (15,307) KSEK as of March 31, 2024. The cash flow for the first quarter of 2024 was negative at -11,942 KSEK. The cash flow from operating activities was negative at -10,983 KSEK. The Board has decided, subject to the approval of the shareholders' meeting, to carry out a preferential rights issue during the spring of 2024, followed by subscription options of series TO5 later in the fall. The preferential rights issue is covered by 70% of subscription commitments and guarantee commitments. There is a possible risk that the group's liquidity over the next 12 months may prove insufficient, depending on the outcome of these issuances. However, the Board believes that the prospects for securing capital are favorable.

**Equity** – The group's equity as of March 31, 2024, amounted to 64,353 (82,737) KSEK, resulting in a solidity of 71% (86%).

**Liabilities** – The group's short-term liabilities amounted to 26,352 (13,198) KSEK as of March 31, 2024. Interest-bearing liabilities amount to 16,945 KSEK, of which 8,076 KSEK relates to deferral at the Swedish Tax Agency and the remainder to a short-term loan.

**INCOME STATEMENT**

**Peptonic Group**

KSEK	Note	3 mon Jan-Mar 2024	3 mon Jan-Mar 2023	12 mon Jan-Dar 2023
<b>Operating income</b>				
Sales of products		10 808	8 874	37 118
Other operating income		340	193	1 147
<b>Total operating income</b>		<b>11 148</b>	<b>9 067</b>	<b>38 265</b>
<b>Operating expenses</b>				
Cost of goods		-4 914	-4 005	-20 823
Other external expenses		-8 607	-6 085	-28 839
Personnel costs		-6 436	-4 791	-23 440
Depreciation		-1 574	-840	-6 266
Other operating costs		-15	0	-83
<b>Total operating expenses</b>		<b>-21 546</b>	<b>-15 721</b>	<b>-79 451</b>
<b>Operating loss</b>				
Net financial income		1	316	919
Net financial expense		-261	-1 660	-2 323
<b>Loss before taxes</b>		<b>-10 658</b>	<b>-7 998</b>	<b>-42 589</b>
Taxes		0	0	0
<b>Net loss for the period</b>		<b>-10 658</b>	<b>-7 998</b>	<b>-42 589</b>

**BALANCE SHEET**

**Peptonic Group**

KSEK	Note	31-mar 2024	31-mar 2023	31-dec 2023
<b>Assets</b>				
<b>Non-Current assets</b>				
Intangible assets	2	61 500	49 773	62 538
Tangible assets	3	3 025	4 336	3 783
Financial assets		-	-	-
<b>Total non-current assets</b>		<b>64 525</b>	<b>54 109</b>	<b>66 321</b>
<b>Current assets</b>				
Stock		12 999	17 518	16 002
Other receivables		6 710	7 420	6 082
Tax receivable		-	90	287
Prepaid expenses and accrued income		3 278	1 489	2 910
Liquid assets		3 192	15 307	15 134
<b>Total current assets</b>		<b>26 180</b>	<b>41 825</b>	<b>40 415</b>
<b>Total assets</b>		<b>90 705</b>	<b>95 934</b>	<b>106 736</b>
<b>Equity and liabilities</b>				
<b>Equity</b>				
<b>Ristricted equity</b>				
Share capital		38 371	25 706	38 371
Ongoing right issues		-	-	-
Reserves		5 377	7 392	5 377
Other contributed capital		332 891	316 645	333 041
Profit or loss brought forward incl year result		- 312 286	- 267 007	- 301 466
<b>Total equity</b>		<b>64 353</b>	<b>82 737</b>	<b>75 323</b>
<b>Current liabilities</b>				
Liabilities interest bearing		4 187	2 333	7 556
Trade payables		16 945	6 041	13 779
Other payables		1 768	1 968	5 580
Prepaid income and accrued expenses		3 452	2 855	4 498
<b>Total current liabilities</b>		<b>26 352</b>	<b>13 198</b>	<b>31 414</b>
<b>Total equity and liabilities</b>		<b>90 705</b>	<b>95 934</b>	<b>106 736</b>

**STATEMENT OF CASH FLOW**  
**Peptonic Medical Group**

KSEK	Note	3months Jan-Mar 2024	3months Jan-Mar 2023	12months Jan-Dec 2023
<b>CASH FLOW FROM OPERATIONS</b>				
Operating profit/loss	-	10 658	7 998	42 589
Non-cash flow items		1 540	840	7 054
<b>NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL</b>				
	-	9 118	7 158	35 535
Increase (-) decrease (+) inventory		1 072	2 150	634
Increase (-) decrease (+) receivables	-	1 509	3 420	5 176
Increase (-) decrease (+) liabilities	-	1 278	8 623	2 815
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>				
	-	10 833	7 353	33 808
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Investment in immaterial assets, net	-	394	451	1 285
Investment in material asset, incl subsidiaries	-	96	101	646
Aquisition of business	-	-	-	14 413
Impact Lune Group Oy	-	322	-	0
Group adjustments asset value cuurency impact	-	147	819	2 705
<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>				
	-	959	1 371	19 050
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Rights issue	-	-	54 983	87 243
Issue expenses	-	150	10 520	13 718
Bridgeloan	-	-	16 840	9 101
<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>				
	-	150	27 623	64 425
<b>TOTAL CASH FLOW FOR THE YEAR</b>				
	-	11 942	11 741	11 568
Cash and cash equivalents at beginning of period		15 134	3 566	3 566
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</b>				
		3 192	15 307	15 134

**FINANCIAL INFORMATION – PATRENT COMPANY Peptonic Medical AB**

The merger with Pharmiva was integrated into the parent company during the fourth quarter of 2023. Pharmiva's accumulated results before the merger date and most merger-related costs were accounted for directly against the equity in the parent company and do not affect the income statement. Starting from the merger date on November 21, Pharmiva is included in the group's operating results and balance sheet. During the first quarter of 2024, only Lune Group Oy is included in the results until March 12. It is important to note that the figures for the first quarter of 2024 are not directly comparable to the previous year due to changes in the group structure.

**Revenue** – 3,458 (1,331) KSEK during the first quarter. Other operating revenues for the quarter were 15 (0) KSEK. Compared to the same period last year, the increased sales can be attributed in part to the introduction of new products such as Vernivia, a self-test for urinary tract infection, and a self-test for menopause.

**Operating expenses** – Expenses for the first quarter amounted to -11,951 (-5,868) KSEK. The increase is primarily due to personnel costs and other external costs, mainly related to restructuring costs associated with the merger of Pharmiva and increased headcount. Cost of goods sold during the period was -1,076 (-

456) KSEK, resulting in a gross margin of 69% (66%). A write-down due to Lune Group Oy negatively impacted the result by 740 KSEK in the quarter. Continuous efforts are being made to restructure and streamline the organization after the merger of Pharmiva.

**Result** – The company's result after financial items for the first quarter amounted to -7,416 (-6,024) KSEK.

**Financial position and liquidity**– Cash and bank balances as of December 31 amounted to 1,216 (10,610) KSEK as of March 31. The cash flow for the quarter was negative, amounting to -9,394 KSEK. The cash flow from operating activities was negative at -9,000 KSEK. The board has, subject to approval at the shareholders' meeting, decided to carry out a rights issue in spring 2024, followed by subscription options of series T05 later in the autumn. The rights issue is covered to 70% by subscription commitments and guarantee commitments. There is a possible risk that the group's liquidity over the next 12 months may prove to be insufficient, depending on the outcome of these issuances. However, the board believes that the prospects for securing capital are good.

**Equity** – The company's equity as of March 31, 2024, amounted to 81,707 (89,273) KSEK, resulting in a solvency ratio of 78 (78) percent.

**Liabilities** - The company's liabilities amounted to 23,585 (25,015) KSEK as of March 31, 2024, of which 16,945 KSEK are interest-bearing.

#### INCOME STATEMENT

##### Peptonic Medical - Parent company

KSEK	Note	3 mon Jan-Mar 2024	3 mon Jan-Mar 2023	12 mon Jan-Mar 2023
<b>Operating income</b>				
Sales of products		3 458	1 331	6 593
Internal sales		0	0	0
Other operating income		15	0	96
<b>Total operating income</b>		<b>3 473</b>	<b>1 331</b>	<b>6 689</b>
Operating expenses				
<b>Cost of goods</b>		-1 076	-456	-2 522
Other external expenses		-4 508	-2 978	-13 962
Personnel costs		-4 198	-1 736	-10 740
Depreciation		-1 415	-698	-17 325
Other operating costs		-754	0	-63
<b>Total operating expenses</b>		<b>-11 951</b>	<b>-5 868</b>	<b>-44 613</b>
<b>Operating loss</b>		<b>-8 479</b>	<b>-4 537</b>	<b>-37 924</b>
Net financial income		1 324	140	921
Net financial expense		-261	-1 627	-4 412
<b>Loss before taxes</b>		<b>-7 416</b>	<b>-6 024</b>	<b>-41 415</b>
Taxes		0	0	0
<b>Net loss for the period</b>		<b>-7 416</b>	<b>-6 024</b>	<b>-41 415</b>

**BALANCE SHEET**

**Peptonic Medical AB**

		<b>31-mar 2024</b>	<b>31-dec 2023</b>
KSEK	Note		
<b>Assets</b>			
<b>Non-Current assets</b>			
Intangible assets	2	61 475	62 488
Tangible assets	3	441	448
Financial assets	4	5 992	5 992
<b>Total non-current assets</b>		<b>67 908</b>	<b>68 928</b>
		<b>0</b>	<b>0</b>
<b>Current assets</b>			
Stock		5 251	5 527
Other receivables		2 299	1 864
Group company receivables		27 434	25 713
Prepaid expenses and accrued income		1 184	1 646
Liquid assets		1 216	10 610
<b>Total current assets</b>		<b>37 384</b>	<b>45 360</b>
<b>Total assets</b>		<b>105 292</b>	<b>114 288</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
<b>Restricted equity</b>			
Share capital		38 371	38 371
Development Cost Fund		5 377	5 377
<b>Non-restricted equity</b>			
Share premium reserve non-restricted		332 891	333 041
Profit or loss brought forward		-287 516	-246 100
Net loss for the period		-7 416	-41 415
<b>Total equity</b>		<b>81 707</b>	<b>89 273</b>
<b>Current liabilities</b>			
Trade payables		2 750	3 341
Other payables		16 945	13 668
Group company debts		578	4 707
Prepaid income and accrued expenses		3 312	3 299
<b>Total current liabilities</b>		<b>23 585</b>	<b>25 015</b>
<b>Total equity and liabilities</b>		<b>105 292</b>	<b>114 288</b>



**STATEMENT OF CASH FLOW**  
**Peptonic Medical Group**

		<b>3months</b>	<b>3months</b>	<b>12months</b>
		<b>Jan-Mar</b>	<b>Jan-Mar</b>	<b>Jan-Dec</b>
		<b>2024</b>	<b>2023</b>	<b>2023</b>
KSEK				
<b>CASH FLOW FROM OPERATIONS</b>				
Operating profit/loss	-	7 416	- 6 024	- 41 415
Non-cash flow items		1 414	696	17 325
<b>NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL</b>	<b>-</b>	<b>6 002</b>	<b>- 5 328</b>	<b>- 24 089</b>
Increase (-) decrease (+) inventory		278	- 729	- 2 406
Increase (-) decrease (+) receivables	-	1 694	- 3 795	- 6 491
Increase (-) decrease (+) liabilities	-	1 432	- 8 817	- 3 667
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>-</b>	<b>8 850</b>	<b>- 18 669</b>	<b>- 36 653</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Investment in immaterial assets, net	-	394	- 331	- 1 266
Investment in material asset, incl subsidiaries		-	-	- 4 883
Aquisition of business		-	-	- 406
Group adjustments asset value currency impact		-	-	-
<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>	<b>-</b>	<b>394</b>	<b>- 331</b>	<b>- 6 555</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Rights issue		-	54 983	72 829
Issue expenses	-	150	- 10 520	- 13 718
Bridgeloan		-	- 14 531	- 5 664
<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>	<b>-</b>	<b>150</b>	<b>29 932</b>	<b>53 447</b>
<b>TOTAL CASH FLOW FOR THE YEAR</b>	<b>-</b>	<b>9 394</b>	<b>10 932</b>	<b>10 239</b>
Cash and cash equivalents at beginning of period		10 610	371	371
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</b>		<b>1 216</b>	<b>11 303</b>	<b>10 610</b>

## NOTES

### Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act (Chapter 9. Interim Report) and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and consolidated (K3-rules). The accounting principles are unchanged compared to the previous year.

### Note 1 - Transactions with Related Parties

#### Group/Parent Company

During the period, no companies represented by board members have been engaged on a consultancy basis.

### Note 2 - Intangible Fixed Assets

#### Group/Parent Company

Patent and development costs are capitalized and depreciated over 20 years from the time the first revenue is generated for the group, with depreciation commencing from the full year 2019. Capitalized patent and development costs are expected to generate future revenues for the group. In the balance sheet, patent and development costs are recorded at cost, reduced by accumulated depreciation.

**Note 2**

<b>Peptonic Medical AB</b>	<b>31-mar</b>	<b>31-mar</b>
<b>Capitalized development costs</b>	<b>2024</b>	<b>2023</b>
<i>Accumulated acquisition value</i>		
Opening balance	63 231	51 873
Reclassification	-	-
Capitalizations during the period	-	-
Fusion	-	-
	<b>63 231</b>	<b>51 873</b>
<i>Accumulated depreciation value</i>		
Deprecation of the year	-16 343	-9 892
Reclassification	-955	-618
Reclassification	-	-
Fusion	-	-
Outgoing accumulated depreciation	<b>-17 298</b>	<b>-10 510</b>
<b>Net booked amount at end of period</b>	<b>45 933</b>	<b>41 363</b>
<b>Patents and licenses</b>		
<i>Accumulated acquisition value</i>		
Opening balance	12 161	9 177
Sold out and other disposals	-	-
Reclassification	-	-
Capitalizations during the period	394	332
Fusion	-	-
	<b>12 555</b>	<b>9 509</b>
<i>Depreciation</i>		
Opening accumulated depreciation value	-2189	-1455
Deprecation of the year	-161	-77
Sold out and other disposals	-	-
Reclassification	-	-
Fusion	-	-
Outgoing accumulated depreciation	<b>-2350</b>	<b>-1532</b>
<b>Net booked amount at end of period</b>	<b>10 206</b>	<b>7 977</b>
<b>Goodwill</b>		
<i>Accumulated acquisition value</i>		
Opening balance	5 821	23 495
Sold out and Other disposals	-	-
Capitalizations during the period	-	-
	<b>5 821</b>	<b>-</b>
<i>Depreciation at the beginning of the period</i>		
Sales/disposals	-194	-23 495
Deprecation for the period	-	-
Deprecation for the period	<b>-291</b>	<b>-</b>
Accumulated depreciation at the end	<b>-485</b>	<b>-23 495</b>
<b>Net booked amount at end of period</b>	<b>5 336</b>	<b>0</b>
<b>Total intangible assets</b>	<b>61 475</b>	<b>49 340</b>

**Note 3 – Tangible fixed assets**  
**Group/Parent Company**

In the group, there are activated tools for the production of products.

**Note 4 – Financial fixed assets**  
**Parent Company**

As of March 31, 2024, the holding of shares in wholly-owned subsidiaries amounts to a total of 5,992 (12,892) KSEK.

## RISKS AND UNCERTAINTIES

The business risks, risk management of the group and parent company, as well as the management of financial risks, are extensively described in the annual report for 2023, submitted in May 2024, available on the company's website: [www.peptonicmedical.se/financial-information/](http://www.peptonicmedical.se/financial-information/)

## FINANCING

Efforts are being made to secure the financing of the operations, including intensified focus on sales and business development, as well as exploring other alternatives. The Board of Directors continuously evaluates the group's financial position, funding needs, and possible financing alternatives to ensure continuity in operations. With the approval of the shareholders' meeting, the Board plans to carry out a capital raise to secure sufficient liquidity for the next twelve-month period. The Board's assessment is that the company has good prospects for securing the necessary financing.

## AUDIT

This quarterly report has not been subject to review by the company's auditors.

## ASSURANCE

The Board of Directors and the Chief Executive Officer certify that the quarterly report provides a fair overview of the company's operations, position, and results.

## FINANCIAL CALENDER

Annual general meeting	2024-05-21
Quarterly report, 2	2024-08-13
Quarterly report, 3	2024-11-06
Year-end report, 2024	2025-02-21

The Annual General Meeting will be held on May 21, 2024, in Stockholm. The annual report is available on the Company's website, [www.peptonicmedical.se](http://www.peptonicmedical.se).

## Stockholm, May 7th, 2024

Anders Blom, Chairman of the board	Daniel Rudeklint, Board member
Anders Norling, Board member	Tarek Shoeb, Board member
Kristina Ingvar, Board member	Anna Linton, CEO

For further information, please contact: Anna Linton, CEO of PEPTONIC Medical AB. Tel: +46 70 244 92 07.

*Note: This document contains certain information about the external environment and the future. These details should be considered solely as reflecting the current perception. No guarantees can be given that this information is accurate.*